Dimitry Nuyten

Directeur Technique/Scientifique/R&D chez ARCUS BIOSCIENCES, INC.

Fortune : 203 569 $ au 30/04/2024

48 ans

Health Technology

Consumer Services

Postes actifs de Dimitry Nuyten

Sociétés	Poste	Début	Fin
ARCUS BIOSCIENCES, INC.	Directeur Technique/Scientifique/R&D	01/08/2022	-

Sociétés	Poste	Début	Fin
NEKTAR THERAPEUTICS	Directeur Technique/Scientifique/R&D	19/07/2021	01/04/2022
PFIZER, INC.	Corporate Officer/Principal	01/07/2013	01/03/2019
BRISTOL-MYERS SQUIBB COMPANY	Directeur Technique/Scientifique/R&D	01/03/2008	01/06/2013
CHINOOK THERAPEUTICS, INC.	Directeur Technique/Scientifique/R&D	22/04/2019	-

University of Groningen	Doctorate Degree
University of Amsterdam	Doctorate Degree

Internationale

Etats-Unis	6
Pays-Bas	3

Opérationnelle

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	2
Corporate Officer/Principal	1

Sectorielle

Health Technology	6
Consumer Services	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	4
PFIZER, INC.	Health Technology
BRISTOL-MYERS SQUIBB COMPANY	Health Technology
NEKTAR THERAPEUTICS	Health Technology
ARCUS BIOSCIENCES, INC.	Health Technology

Entreprise privées	1
Aduro BioTech, Inc. Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.	Health Technology

Entreprise privées

Health Technology